About
Newman Knowlton is a clinical-trials and biostatistics professional at Pentara Corporation, where he currently serves as VP of Corporate Development. Pentara says he joined in 2018, earned an M.S. in Quantitative Psychology from McGill University, contributed to multiple neurodegenerative-disease papers, and led work on an NDA for the ALS drug AMX0035. His visible public profile is centered on Alzheimer's and ALS research, statistical methodology, and conference presentations rather than investing.
Areas of interest
Alzheimer's diseaseALSneurodegenerative diseasebiostatisticsclinical trialsregulatory strategyAI in clinical research